Lipella Pharmaceuticals I...
(LIPO)
undefined
undefined%
At close: undefined
2.55
-2.67%
Pre-market Dec 16, 2024, 07:29 AM EST
Company Description
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.
It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus.
The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Lipella Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Dec 19, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Dr. Jonathan Kaufman M.B.A., Ph.D. |
Contact Details
Address: 7800 Susquehanna St. Pittsburgh, Pennsylvania United States | |
| Website | https://www.lipella.com |
Stock Details
| Ticker Symbol | LIPO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001347242 |
| CUSIP Number | 53630L100 |
| ISIN Number | US53630L1008 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jonathan Kaufman M.B.A., Ph.D. | Co-Founder, Chairman, Chief Executive Officer, President, Secretary & Treasurer |
| Douglas Johnston CPA | Chief Financial Officer |
| Dr. Michael B. Chancellor M.D. | Co-Founder, Chief Medical Officer & Director |
| Katie Johnston | Controller |
| Michele Gruber | Director of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 8-K | Current Report |
| Dec 06, 2024 | DEFA14A | Filing |
| Dec 06, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | DEF 14A | Filing |
| Nov 07, 2024 | 8-K | Current Report |
| Nov 01, 2024 | PRE 14A | Filing |
| Nov 01, 2024 | 8-K | Current Report |